Milnacipran does not directly improve sleep continuity and architecture but its impact on sleep improvement can be attributed to its effectiveness in reducing pain, according to data presented at SLEEP 2015.
The effect of cognitive behavioral therapy for insomnia (CBT-I) does not vary based on medication use or comorbidity, according to data presented at SLEEP 2015.
A case study presented at SLEEP 2015 suggest that an influenza vaccination may have triggered status cataplecticus in the female patient with known narcolepsy.
According to data presented at SLEEP 2015, children with obstructive sleep apnea syndrome (OSAS) that adhered to positive airway pressure (PAP) therapy demonstrated improvements in quality of life (QoL).
Pharmacotherapy improves multiple domains of functioning in patients with central disorders of hypersomnolence (CDH) in a “real-world” tertiary care setting, according to data presented at SLEEP 2015.
Sodium oxybate improved health-related quality-of-life (HRQoL) measures in patients with narcolepsy in a dose-dependent manner, results from a randomized placebo-controlled trial presented at SLEEP 2015 have found.
Lemborexant (E2006), a dual orexin receptor antagonist (DORA) under development for insomnia disorder, led to a decrease in latency to persistent sleep (LPS) and wake after sleep onset (WASO) and an increase in sleep efficiency (SE), according to data presented at SLEEP 2015.
The orexin receptor antagonist suvorexant improves sleep in patients with insomnia, analysis of pooled results of two Phase 3 clinical trials presented at SLEEP 2015 have found.
Please login or register first to view this content.